TheraVet (ISIN: BE0974387194 - ticker: ALVET) today announces a strategic transformation project with H4Orphan aimed at ...

Sep. 27, 2023 — Lung fibrosis is a debilitating disease affecting nearly 250,000 people in the U.S. alone with 50,000 new cases reported each year. There is currently no cure and limited ...

This blog describes a typical ILD patient journey from the initial diagnosis through its long-term management to end-of-life ...

People with certain lung conditions like chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis are more likely to experience a collapsed lung ... and the stomach can cause chest ...

MP Cariappa, Public Health Specialist, Advisor, Tata Trusts shares inputs on understanding chronic lung diseases. He is also ...

More than 4,000 doses of PRM-151 have been administered to more than 250 patients over 6 years, and Promedior has just completed phase 2 trials in patients with idiopathic pulmonary fibrosis (IPF ...

chronic obstructive pulmonary disease, cystic fibrosis, asthma, interstitial lung disease, bronchiectasis, benign and malignant neoplasms, and lung transplantation. The Lung Institute has developed a ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...

Clear, bubbly phlegm may be a sign of pulmonary edema ... Yellow-green phlegm is also a common symptom of cystic fibrosis. Cystic fibrosis causes a buildup of mucus within the lungs and digestive ...

Help us make Medscape the best clinical resource possible. Please use this form to submit your questions or comments on how to make this resource center more useful to clinicians.

There are about 200 different conditions that are categorized under ILD. The conditions commonly considered as ILDs include various disorders such as idiopathic pulmonary fibrosis (IPF), connective ...

The Program for Pulmonary Fibrosis and Interstitial Lung Disease's mission is to provide state of the art evaluation and treatment for patients with interstitial lung diseases (ILD). The University of ...